Euroscreen S.A.

Under the updated terms of the agreement, Euroscreen will receive R&D payments, milestone payments and royalties for succesful programs that result from this collaboration, which will continue through 2009.

"This relationship with Cephalon has become a significant drug development partnership to advance a preclinical candidate for their pipeline, and evidences the positive relationship and our deliverables to date" said Jean Combalbert, President & CEO of Euroscreen.  "In addition to our past two years refocusing on our own internal drug discovery programs, this partnership is a key element of value creation for Euroscreen's future."

We are please to focus this collaboration on a specific, preclinical, drug development program with Euroscreen to further enhance and complement our drug discovery pipeline," said Mike Williams, Vice President, Discovery Research of Cephalon.

-ends-

For further licensing Information, please contact:

Euroscreen SA
Tel: +32 71 348 500
Email: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

Jean Combalbert, Ph.D.
Chief Executive Officer

Al Gray, Ph.D.
Director, Business Development

About Euroscreen S.A.

EUROSCREEN is a privately held preclinical-stage biopharmaceutical company based in Brussels Belgium, focused on the discovery and development of small molecule drugs for unmet medical needs.  Founded in 1994, as a spin-off of the "Université Libre de Bruxelles", initially developing and commercializing G Protein-Coupled Receptors (GPCR) reagents, EUROSCREEN is now developing a pipeline of preclinical candidates targeting proprietary GPCR, such as CCR5, as well as several preclinical-stage collaborations with partners, using its worldwide recognized expertise on this critical class of drug targets.

EUROSCREEN pursues a dual business model strategy of combining its internal programs on high value targets (EUROSCREEN DRUG DISCOVERY) with its fully dedicated Business Unit (EUROSCREEN FAST) providing GPCR customized screening and other services for biotech and pharmaceutical companies around the world.

EUROSCREEN has also developped a broad target portfolio for licensing intellectual property rights to pharmaceutical companies for the development of therapeutic drugs that act through these targets, including CCR5, Chemerin receptor, GPR43, GPR7/8, ORL1-R, FPRL2, purinergic receptors (P2Y4, P2Y11 and P2Y13) and SHIP2.

EUROSCREEN has discovery and licensing partnerships with Alchemia, AstraZeneca, Boehringer-Ingelheim, Cephalon, GNF, Grunenthal, HGS, ICOS owned by Lilly, Medarex, Monogram Biosciences, Novartis and Pfizer.

Founded in 1987, Cephalon Inc. is an international biopharmaceutical company dedicated to the discovery, development and commercialization of innovative products.  Cephalon is a leader in the discovery and development of products to treat central nervous system and oncologic disorders.  The company's scientific exploration has led to the creation of new chemical entities focused on GPCR's and cell signaling pathways that are involved in the pathogenesis of disease.